Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II b (Randomized Controlled) Study of Atezolizumab Combined to BEGEV Regimen as First Salvage Treatment in Patients With Relapsed or Refractory Hodgkin's Lymphoma Candidate to Autologous Stem-Cell Transplantation

NCT05300282 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT05300282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05300282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II b (Randomized Controlled) Study of Atezolizumab Combined to BEGEV Regimen as First Salvage Treatment in Patients With Relapsed or Refractory Hodgkin's Lymphoma Candidate to Autologous Stem-Cell Transplantation
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 27, 2023
Completion date
December 15, 2029
Enrollment
122 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory hodgkin's lymphoma